Showing 2031-2040 of 5627 results for "".
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- Laser Vision Correction Market Growth Continues for Third Consecutive Yearhttps://modernod.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/US laser vision correction procedure volume grew for the third straight year in 2018, reflecting continued strong demand for LASIK and other forms of laser vision correction, according to figures released by The Refra
- Silgan to Debut Iridya Preservative-Free Multi-dose Eye Dropperhttps://modernod.com/news/silgan-to-debut-iridya-preservative-free-multi-dose-eye-dropper/2476322/Silgan Dispensing will highlight its newest ophthalmic dispensing solution, Iridya, at this year’s Pharmapack, Europe’s dedicated pharmaceutical packaging and drug delivery event. Iridya is a next-generation, preservative-free multi-dose, eye dropper that improves on existing technology by
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu
- Beaver-Visitec International to Acquire PhysIOL Grouphttps://modernod.com/news/tpg-capital-backs-bvi-to-acquire-physiol-group-sa/2476246/Beaver-Visitec International (BVI) announced it has signed a definitive agreement to acquire PhysIOL Group, a Belgium-based ophthalmic company specializing in the research, development, and manufacture of IOLs, from TA Associates. Financial terms of the transaction were not disclosed.
- Report: Laser Vision Correction Procedure Volume Increases for Third Straight Yearhttps://modernod.com/news/report-laser-vision-correction-procedure-volume-increases-for-third-straight-year/2479719/Laser vision correction procedure volume in the United States increased for the third year in a row, indicating a growing demand for LASIK and other laser vision correction procedures, according to data released by the Refractive Surgery Council (RSC). Year-to-date laser vision correction
- EyeMD EMR Healthcare Systems to Debut its EyeMD Electronic Medical Records 2.0 Releasehttps://modernod.com/news/eyemd-to-debut-its-eyemd-electronic-medical-records-2-0-release/2479739/EyeMD EMR Healthcare Systems, a provider of electronic medical records software designed specifically for ophthalmologists, announced the debut of EyeMD EMR 2.0 at the 2018 American Academy of Ophthalmology’s Annual Meeting in Chicago. “EyeMD EMR 2.0 is the result of years of research and
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that